Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

17.1K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

278
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
278
Experimental RNAi02:15

Experimental RNAi

6.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reversible & Microbubble Concentration-Dependent Permeabilization of an <i>In Vitro</i> Human Endothelial Barrier to Small Molecules Using Ultrasound: Implications for Neurodegenerative Diseases Therapy.

Molecular pharmaceutics·2026
Same author

COQ7-Related Neuropathy: Two New Cases and Review of the Literature.

Journal of the peripheral nervous system : JPNS·2026
Same author

Anchoring ALS Prognosis: Neurofilament Light Chain Outperforms Inflammatory, Metabolic, and CNS Barrier Biomarkers in the METABALS Cohort.

Molecular neurobiology·2026
Same author

From Mutation to Manifestation: Penetrance in Amyotrophic Lateral Sclerosis.

Genes·2026
Same author

Analysis of mitochondrial DNA heteroplasmy in sporadic ALS suggests technical limitations rather than disease association.

Neurobiology of disease·2026
Same author

Large-scale exome analyses reveal new rare variant contributions in amyotrophic lateral sclerosis.

Nature genetics·2026
Same journal

Clonal hematopoiesis in Alzheimer's brain: Protective, pathogenic, and context-dependent?

Trends in molecular medicine·2026
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
Same journal

Targeting ferroptosis halts graft deterioration in transplantation.

Trends in molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Oct 1, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.9K

InFUSing antisense oligonucleotides for treating ALS.

Philippe Codron1, Julien Cassereau2, Patrick Vourc'h3

  • 1Centre de ressources et de compétences sur la SLA, Centre Hospitalier Universitaire d'Angers, Angers, France; Laboratoire de Neurobiologie et Neuropathologie, Centre Hospitalier Universitaire d'Angers, Angers, France; Univ Angers, Inserm, CNRS, MITOVASC, SFR ICAT, Angers, France.

Trends in Molecular Medicine
|March 5, 2022
PubMed
Summary
This summary is machine-generated.

Amyotrophic lateral sclerosis (ALS) research suggests FUS mutations cause toxic gain of function. Lowering FUS protein levels may offer a promising therapeutic strategy for FUS-ALS patients.

Keywords:
FUSTDP-43amyotrophic lateral sclerosisantisense oligonucleotide

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.8K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

18.9K

Related Experiment Videos

Last Updated: Oct 1, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.9K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

13.8K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

18.9K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • The precise molecular mechanism underlying FUS-related amyotrophic lateral sclerosis (ALS) remains a subject of ongoing debate.
  • Key questions revolve around whether FUS mutations result in a loss of normal function or a toxic gain of function.

Purpose of the Study:

  • To investigate the functional consequences of FUS mutations in ALS.
  • To evaluate the therapeutic potential of modulating FUS protein levels.

Main Methods:

  • Analysis of FUS protein function in cellular and/or animal models of FUS-ALS.
  • Assessment of the impact of reducing wild-type and mutant FUS levels on disease phenotypes.

Main Results:

  • Evidence suggests that FUS mutations contribute to a gain of toxic function in the context of ALS.
  • Reducing FUS protein levels demonstrated a potential therapeutic benefit.

Conclusions:

  • FUS mutations likely induce a toxic gain of function, driving FUS-ALS pathogenesis.
  • Strategies aimed at lowering FUS levels represent a promising therapeutic avenue for FUS-related ALS.